文献速递心力衰竭与心肌病

不同地域急性心衰患者长期结局与生物学性别的关联

The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions.
PubMed 文献 · Eur Heart J · 2020-01-01

GREAT中女性出院时ACEI联合β受体阻滞剂处方率低于男性(50% vs 57%,P=0.001)。

要点

  • 急性心衰女性1年全因死亡风险低于男性,GREAT中HR 0.86,OPTIMIZE-HF中HR 0.93。
  • 性别差异主要见于东北亚(HR 0.76),其他国家未观察到显著差异。
  • 女性出院时ACEI联合β受体阻滞剂处方率低于男性(50% vs 57%)。

核心结论

  • 全球范围内急性心衰女性1年全因死亡风险低于男性,且接受循证治疗更少。
  • 性别与结局的关联存在地域差异,需进一步研究。

研究设计与样本

  • 收集临床特征和出院时用药,采用Cox比例风险回归校正基线特征评估性别与1年死亡的风险比。

主要发现

  • GREAT中女性出院时ACEI联合β受体阻滞剂处方率低于男性(50% vs 57%,P=0.001)。

临床怎么用

  • 临床中应关注急性心衰女性循证治疗不足的问题,评估ACEI与β受体阻滞剂联合处方的合理性。
  • 解读性别与预后关联时需考虑地域差异,东北亚人群证据更为显著。

局限性

  • 原文未系统报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Recent data from national registries suggest that acute heart failure (AHF) outcomes might vary in men and women, however, it is not known whether this observation is universal. The aim of this study was to evaluate the association of biological sex and 1-year all-cause mortality in patients with AHF in various regions of the world. METHODS AND RESULTS: We analysed several AHF cohorts including GREAT registry (22 523 patients, mostly from Europe and Asia) and OPTIMIZE-HF (26 376 patients from the USA). Clinical characteristics and medication use at discharge were collected. Hazard ratios (HRs) for 1-year mortality according to biological sex were calculated using a Cox proportional hazards regression model with adjustment for baseline characteristics (e.g. age, comorbidities, clinical and laboratory parameters at admission, left ventricular ejection fraction). In the GREAT registry, women had a lower risk of death in the year following AHF [HR 0.86 (0.79-0.94), P < 0.001 after adjustment]. This was mostly driven by northeast Asia [n = 9135, HR 0.76 (0.67-0.87), P < 0.001], while no significant differences were seen in other countries. In the OPTIMIZE-HF registry, women also had a lower risk of 1-year death [HR 0.93 (0.89-0.97), P < 0.001]. In the GREAT registry, women were less often prescribed with a combination of angiotensin-converting enzyme inhibitors and beta-blockers at discharge (50% vs. 57%, P = 0.001). CONCLUSION: Globally women with AHF have a lower 1-year mortality and less evidenced-based treatment than men. Differences among countries need further investigation. Our findings merit consideration when designing future global clinical trials in AHF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Motiejūnaitė J, Akiyama E, Cohen-Solal A, et al. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. Eur Heart J. 2020. PMID: 32125360. doi:10.1093/eurheartj/ehaa071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。